You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Final Comments to DC on Licensure of Pharmaceutical Detailers

<p>
The Biotechnology Industry Organization (BIO) thanks you for the opportunity to comment on the District of Columbia (the District) Department of Health&#39;s proposed rules on the reporting requirements for &quot;Pharmaceutical Detailers.&quot; These proposed rules address the content and reporting requirements for the licensure and regulation of the practice of pharmaceutical detailing in the District as defined in Title I of the SafeRx Amendment Act of 2008 (D.C. Law 0131; 55 DCR 4462, published on April 25, 2008) (the Act).</p>

Subject: Department of Health, Chapter 83, Pharmaceutical Detailers, of Title 17, Business Occupations and Professions, of the District of Columbia Municipal Regulations (DCMR)

Dear Sir/Madam:

The Biotechnology Industry Organization (BIO) thanks you for the opportunity to comment on the District of Columbia (the District) Department of Health's proposed rules on the reporting requirements for "Pharmaceutical Detailers." These proposed rules address the content and reporting requirements for the licensure and regulation of the practice of pharmaceutical detailing in the District as defined in Title I of the SafeRx Amendment Act of 2008 (D.C. Law 0131; 55 DCR 4462, published on April 25, 2008) (the Act).

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.